OTC:INTI | Free Cash Flow | Inhibitor Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2012-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$1.08M
2025-12-31-$601,165.00
2025-03-31-$1.28M
2024-12-31-$771,441.00
2024-03-31-$1.16M
2023-12-31-$697,706.00
2023-03-31-$757,283.00
2022-12-31$11.9M
2022-03-31-$44,188.00
2021-12-31-$22,661.00
2021-03-31-$91,870.00
2020-12-31-$16,648.00
2020-03-31-$501,128.00
2019-12-31-$568,370.00
2019-03-31-$977,989.00
2018-12-31-$832,113.00
2018-03-31-$1.13M
2017-12-31-$543,248.00
2017-03-31-$867,878.00
2016-12-31-$1.21M
2016-03-31-$482,822.00
2015-12-31-$641,827.00
2015-03-31-$281,210.00
2014-12-31-$518,784.00
2014-03-31-$108,505.00
2013-12-31-$169,437.00
2013-03-31-$81,230.00
2012-12-31-$65,716.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$3.23M
2024-12-31-$3.23M
2023-12-31-$2.7M
2022-12-31$11.74M
2021-12-31-$220,433.00
2020-12-31-$825,357.00
2019-12-31-$2.71M
2018-12-31-$3.71M
2017-12-31-$2.91M
2016-12-31-$3.76M
2015-12-31-$2.26M
2014-12-31-$1.3M
2013-12-31-$1.22M
2012-12-31-$464,266.00